<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: BAY 56-3722 (formerly BAY 38-3441) is a glycoconjugated campthotecin, which was considered an attractive drug to assess in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>PATIENT AND METHODS: Phase II study design evaluating the antitumor activity of BAY 56-3722 i.v </plain></SENT>
<SENT sid="2" pm="."><plain>320 mg/m(2) daily for 3 days every 3 weeks in patients with recurrent or metastatic inoperable <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> resistant to irinotecan </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Twenty-four patients received the study treatment </plain></SENT>
<SENT sid="4" pm="."><plain>Triggered by adverse events in two other studies with this compound the study was put on a clinical hold while the safety data were reviewed for the entire program </plain></SENT>
<SENT sid="5" pm="."><plain>After the review Bayer decided to withdraw BAY 56-3722 from <z:hpo ids='HP_0000001'>all</z:hpo> clinical investigations </plain></SENT>
<SENT sid="6" pm="."><plain>DISCUSSION: We felt it was our obligation to share this interrupted phase II study for two reasons: to report the fate of <z:chebi fb="0" ids="27656">camptothecin</z:chebi> glycoconjugate and to report the unique situation of a clinical hold during a phase II study </plain></SENT>
</text></document>